Bristol Myers (BMY) Stock: Here’s What You Need To Know

Bristol Myers (NYSE:BMY) On August 5, 2016 Bristol Myers had a very rough day with respect to one of its targets in the pipeline.  The company’s PD-1 immune checkpoint inhibitor, known as Opdivo, failed to meet the primary endpoint of a phase 3 clinical trial. Bristol Myer’s stock did not have a good day after … Read more

Bind Therapeutics (BIND) Stock: Heres What You Need To Know

Bind Therapeutics (NASDAQ:BIND) On July 1, 2016 Bind Therapeutics announced that it had agreed to a stalking horse bid from Pfizer. The company said that it had filed a motion in court for a purchase agreement whereby Pfizer would acquire Bind’s assets. Investors greatly cheered this news and the stock nearly doubled to 0.78 cents … Read more

Biotech Stock News (AZN) (AMGN) (NVS) (LLY) (HRTX) (MRK)

AstraZeneca (NYSE:AZN) & Amgen (NASDAQ:AMGN) On May 26, 2015 both AstraZeneca and Amgen announced that it would end a partnership established back in 2012 for a psoriasis drug collaboration. This collaboration established in 2012 allowed Astrazeneca to work on five antibody compounds from Amgen’s anti-inflammation drug pipeline. Amgen received an upfront payment of at least … Read more

Biotech Stock News (CLDN) (BLUE) (QURE) (ONCE) (CANF) (AMGN) (MRK) (BMY)

Celladon Corporation (NASDAQ:CLDN) On April 26, 2015 Shares of Celladon Corporation tumbled 80% in one day after the company reported that its phase 2 trial using Mydicar to treat heart failure patients failed to meet on both the primary endpoint and the secondary endpoint. The phase 2 trial was known as CUPID-2 and recruited up … Read more

Biotech Stock News (HZNP)(HPTX)(XON)(SRPT)(MDVN)(ALPMY)(AZN)

Horizon Pharma (NASDAQ:HZNP) Shares of Horizon Pharma ended the day up 18% on March 30, 2015 after the company announced that it would acquire Hyperion Therapeutics (NASDAQ:HPTX) for $955.7 million dollars. Although one thing to note is that this deal for $955.7 million dollars will be a mix of a cash and debt deal. The … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported  positive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more